PYPDHealthcare · BiotechnologyThe 5 Wall Street analysts covering PolyPid Ltd. hold a median 12-month price target of $12 — +114.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 75 of 100 as at 29 Oct 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores PolyPid Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Volatility (97): The share price has been relatively steady.
Quality (16): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on PYPD, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +114.7% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 27 Oct 2026 | Oppenheimer | Initiates | Outperform | $10 |
| 21 July 2026 | HC Wainwright & Co. | Reiterates | Buy | $13 |
| 11 Feb 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 11 Feb 2026 | HC Wainwright & Co. | Reiterates | Buy | $13 |
| 13 Nov 2025 | Roth Capital | Maintains | Buy | — |
| 14 Aug 2025 | Craig-Hallum | Maintains | Buy | — |
| 13 Aug 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 18 June 2025 | Roth Capital | Maintains | Buy | — |
| 17 June 2025 | JMP Securities | Maintains | Market Outperform | — |
| 9 June 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 5 June 2025 | Roth Capital | Initiates | Buy | — |
| 2 June 2025 | HC Wainwright & Co. | Assumes | Buy | $11 |
| 14 Apr 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 26 Dec 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 16 Dec 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 4 Nov 2024 | Craig-Hallum | Initiates | Buy | — |
| 2 Oct 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 15 Aug 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 18 June 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 9 May 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
PYPD appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 29 Oct 2026, PolyPid Ltd. returned +47.1% against +13.1% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 87% of US stocks
Cheaper than 4% of US stocks
Cheaper than 78% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 6% of US stocks
Higher than 4% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
PolyPid Ltd. has a market value of $117.2M and an enterprise value of $112.2M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$31.5M.
Diluted earnings per share, trailing twelve months: $−1.48.
Trailing P/E: −2.7×; forward P/E: −5.5× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
PolyPid Ltd. employs 69 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own PolyPid Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Seeking Alpha published a transcript of PolyPid Ltd.’s Analyst/Investor Day.
Why it matters — The transcript provides PYPD watchers with a record of the company’s remarks at its Analyst/Investor Day.
PolyPid said it will report its third-quarter 2026 financial results and operational highlights before U.S. markets open on November 11, 2026.
Why it matters — The announcement gives PYPD watchers the date and timing of the company’s next financial and operational update.
At an investor day, PolyPid outlined plans to expand its commercial and development strategy through 2030. The company is approaching a November 28, 2026 FDA action date for D-PLEX100, a surgical-site infection prevention product candidate.
Why it matters — The update gives PYPD watchers a timeline for a regulatory decision and a broader view of the company’s plans through 2030.
PolyPid introduced PD01B, a Kynatrix-based candidate for localized, controlled-release antibiotic treatment of diabetic foot infections, planned for development as a new NDA. The company expects a pre-IND meeting and first-in-human study in the second half of 2027, and said scheduled FDA interactions for D-PLEX ₁₀₀ remain on track for its November 28, 2026 PDUFA goal date.
Why it matters — The announcement adds a candidate to PolyPid’s pipeline while also providing an update on the regulatory timeline for D-PLEX ₁₀₀.
Benzinga’s article reports that Wall Street analysts changed their outlooks on several companies, highlighting five initiations for Tuesday. The supplied excerpt does not identify PolyPid or state an analyst action for PYPD.
Why it matters — A PYPD watcher should note that the excerpt provides no specific analyst coverage information about PolyPid.
The 5 Wall Street analysts covering PolyPid Ltd. have a median 12-month price target of $12, with estimates ranging from $8 to $14. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 5 analysts covering PolyPid Ltd., 5 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks PolyPid Ltd. 75 out of 100 across roughly 4,600 US stocks as at 29 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 29 Oct 2026, PolyPid Ltd. ranks 75 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (97 of 100).
No one can know that. What the data says: the median 12-month target from 5 analysts implies +114.7% from the last close, and Ticker Nerd's factor model ranks PolyPid Ltd. 75 out of 100 as at 29 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering PolyPid Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PYPD are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $8 to $14 over the next 12 months.
PolyPid Ltd. returned +47.1% over the 12 months to 29 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
PolyPid Ltd. is a biopharmaceutical company focused on developing long-acting, locally administered therapeutics designed to deliver treatment precisely at the site of care.
The most recent item we track (Seeking Alpha, 29 Oct 2026): "PolyPid Ltd. (PYPD) Analyst/Investor Day Transcript". Seeking Alpha published a transcript of PolyPid Ltd.’s Analyst/Investor Day.
PolyPid Ltd. is a biopharmaceutical company focused on developing long-acting, locally administered therapeutics designed to deliver treatment precisely at the site of care. Its core platform, PLEX, is used to create controlled-release drug formulations that aim to improve therapeutic performance and address unmet medical needs across surgical care and other specialty areas. The company’s lead product candidate, D-PLEX100, is being developed for the prevention of surgical site infections, while its pipeline also includes oncology-focused programs such as OncoPLEX. PolyPid Ltd. works across clinical development, formulation design, and drug delivery technology, positioning itself in the broader market for targeted medicines and advanced pharmaceutical delivery systems. The company is headquartered in Petach Tikva, Israel.
CEO Ms. Dikla Czaczkes Akselbrad · 69 employees · Israel · https://www.polypid.com
